The Top 5 Biosimilar Articles for the Week of June 23

June 27, 2025

Here are the top 5 biosimilar articles for the week of June 23, 2025.

Eye on Pharma: CHMP Aflibercept Decision; Omalizumab Results; Dupilumab Biosimilar Deal

June 26, 2025

Increasing Biosimilar Use Reflects Changing Practice in Pediatric IBD Care

June 25, 2025

Omalizumab Biosimilar Matches Reference Product in Chronic Spontaneous Urticaria

June 24, 2025

BioRationality: Questioning Experts and Journals Reporting on Biosimilar Bill to Remove Interchangeability

June 23, 2025

Phase 3 Study Reports Similar Efficacy Between SB17, Stelara in Psoriasis

October 19th 2024

By Deana Ferreri, PhD

Article

A phase 3, 28-week comparative clinical trial in patients with moderate to severe plaque psoriasis confirmed similarity of the proposed ustekinumab biosimilar SB17 (Samsung Bioepis) to the reference product (Stelara) in efficacy, safety, pharmacokinetics, and immunogenicity.

The Top 5 Biosimilar Articles for the Week of October 14

October 18th 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of October 14, 2024.

Cost Savings and Efficacy of Biosimilars in Psoriasis Treatment for Veterans

October 17th 2024

By Skylar Jeremias

Article

Biosimilars are safe, effective, and well-tolerated for psoriasis treatment, providing significant cost savings for the Veterans Health Administration, which saved over $67 million in 2023, while highlighting ongoing provider concerns regarding their use.

Revolutionizing Biopharmaceuticals: The EU's Biosimilar Success and Remaining Challenges

October 16th 2024

By Skylar Jeremias

Article

The European Union's (EU) approach to biosimilars has revolutionized the biopharmaceutical market by driving innovation, lowering costs, and increasing adoption; however, there remains a need for more education, real-world evidence, and efforts to address challenges to enhance patient access and affordability.

Eye on Pharma: Aflibercept Legal Drama; PBM, Humira Biosimilars; Denosumab Regulatory Review

October 15th 2024

By Skylar Jeremias

Article

Regeneron appeals legal decision after judge refuses to block an aflibercept biosimilar; Prime Therapeutics, a pharmacy benefit manager (PBM), becomes the latest to offer biosimilars referencing Humira (adalimumab) at a low cost; the FDA and European Medicines Agency accept a denosumab biosimilar candidate for review.

Blue Shield of California Lowers Humira Biosimilar Costs, Challenges PBM Pricing

October 15th 2024

By Cameron Santoro

Article

Blue Shield of California will offer an adalimumab biosimilar at a price that is 75% less than the reference product Humira for the monthly dose.

IQVIA Webinar: Enhancing Regulatory Strategies for Biosimilars and Generics

October 14th 2024

By Skylar Jeremias

Article

During a recent webinar, experts discussed critical regulatory aspects for generics and biosimilars, highlighting strategies for navigating complex approval processes, the importance of local market understanding, and the role of technology in enhancing submission efficiency.

From Skepticism to Success: Insights Into Biosimilar Market Acceptance

October 13th 2024

By Cameron Santoro

Video

Ivo Abraham, PhD, RN, director of the Center for Health Outcomes and PharmacoEconomic Research at the University of Arizona Cancer Center, discusses the potential of biosimilars and challenges in the US, emphasizing partnerships for market growth.

Pharmacokinetic Modeling Proposes Cost-Effective Dosing for Adalimumab, Etanercept Biosimilars

October 12th 2024

By Deana Ferreri, PhD

Article

A UK cohort study used drug concentration samples from rheumatoid arthritis patients starting the adalimumab biosimilar Amgevita and the etanercept biosimilar Benepali to simulate drug levels under standard and alternate dosing schedules, suggesting that personalized dosing could reduce costs while potentially increasing efficacy.

FDA Approves Imuldosa, a Biosimilar to Stelara

October 11th 2024

By Skylar Jeremias

Article

Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.